Arena Pharmaceuticals (LTS:0S54) Institutional Ownership : 69.63% (As of May. 06, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Arena Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arena Pharmaceuticals's institutional ownership is 69.63%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arena Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arena Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 86.27%.

Arena Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Arena Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Institutional Ownership Chart

Arena Pharmaceuticals Historical Data

The historical data trend for Arena Pharmaceuticals can be seen below:

	2021-05-31	2021-06-30	2021-07-31	2021-08-31	2021-09-30	2021-10-31	2021-11-30	2021-12-31	2022-01-31	2022-02-28
Institutional Ownership	86.30	87.23	86.37	84.47	85.77	83.27	83.02	73.08	71.21	69.63

Arena Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Arena Pharmaceuticals (LTS:0S54) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (LTS:0S54) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (LTS:0S54) Headlines

No Headlines